Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zuranolone - SAGE Therapeutics

Drug Profile

Zuranolone - SAGE Therapeutics

Alternative Names: BIIB-125; S 812217; SAGE 217; SGE-797

Latest Information Update: 19 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAGE Therapeutics
  • Developer SAGE Therapeutics; Shionogi
  • Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Cyclopentanes; Mood stabilisers; Nitriles; Phenanthrenes; Pyrazoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Preregistration Major depressive disorder; Postnatal depression
  • Phase III Insomnia
  • Phase II Bipolar depression; Essential tremor; Parkinson's disease
  • No development reported Dyskinesias; Seizures

Most Recent Events

  • 17 Oct 2022 Preregistration for Postnatal depression in USA before October 2022 (PO)
  • 17 Oct 2022 Additional efficacy and adverse events data from a phase III SKYLARK trial in Postpartum depression presented at the 35th European College of Neuropsychopharmacology Congress (ECNP-2022)
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Dyskinesias in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top